How biotechs can strengthen their value story with advanced analytics
Small and emerging companies must make big decisions about what to do with their assets early in development. Should they seek venture capital (VC) funding to develop a product themselves or seek a partner once it shows clinical activity? They need to know their product candidate’s value and commercial viability to make the right decision, including the market size, growth and revenue potential.
Recent advances in machine learning and predictive analytics have empowered health economics and outcomes research (HEOR). Sophisticated tools are now available to help build a data-driven value story that can help attract investors and partners, convince payers, and benefit patients. Here are five ways biotech companies can enhance their value story with advanced analytics.
Related Insights
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Incorporating the patient voice in clinical research: Validation of COAs for a rare disease NDA
Nov 17, 2025
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Whitepaper
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Digital Biomarkers – The Future of Precision Medicine
Jul 21, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022
Related Insights
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Incorporating the patient voice in clinical research: Validation of COAs for a rare disease NDA
Nov 17, 2025
Blog
U.S. price reforms 2022: How can drug manufacturers best prepare for the Inflation Reduction Act?
Aug 17, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Whitepaper
Overview of China's Market Approval Policy Med Insurance Payment System
Apr 7, 2022
Podcast
RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry
Jun 16, 2022
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Digital Biomarkers – The Future of Precision Medicine
Jul 21, 2022
Webinar
China's Market Approval Policy and Medical Insurance Payment System for Rare Disease
Jul 21, 2022